Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.

Antivir Chem Chemother · 2018 · PMC5890541 · PMID 29566538

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

L100I, V108I and Y181C also showed a trend toward increased cross-resistance, but when adjusted for multiple comparisons, these were no longer significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.